A Phase 2 interventional study of Ruxolitinib and Placebo in NSCLC (Non-small Cell Lung Carcinoma), sponsored by Incyte Corporation. Terminated at 30 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-13.
Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Carcinoma, Non-Small-Cell Lung by Incyte Corporation — 1 open to participants now, 1 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Incyte Corporation.
Among the 30 studies in Carcinoma, Non-Small-Cell Lung by Incyte Corporation, this one is the 10th largest by enrollment, is one of 3 that started in 2014, is one of 9 in phase 2, and was the 1st registered.
7,638 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →1 of the 30 studies in Carcinoma, Non-Small-Cell Lung by Incyte Corporation is open now, in 8 countries. Recruiting first, the newest first:
Incyte Corporation · Sites in United States, Australia, Belgium and 5 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 20 · Phase 3 3
First in 2014; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 76 is above the median of 62 across 6,031 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 53 across the 30 interventional studies. Of the 26 that completed or were terminated, 19 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
Incyte Corporation is the lead sponsor of 288 studies on the registry; 33 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
1 of the studies in Carcinoma, Non-Small-Cell Lung by Incyte Corporation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06179160Incyte CorporationA Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | 2027-01-01 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies in Carcinoma, Non-Small-Cell Lung by Incyte Corporation, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to determine if ruxolitinib, in combination with Pemetrexed/Cisplatin and Pemetrexed Maintenance, is safe and effective in the treatment of nonsquamous non-small cell lung cancer (NSCLC) that is Stage IIIB, Stage IV, or recurrent.
The study consisted of an open-label, safety run-in (consisting of 1 to 4 cohorts of 9 participants each), to confirm the safety of ruxolitinib in combination with pemetrexed/cisplatin in participants with nonsquamous non-small cell lung cancer (NSCLC) that is Stage IIIB, Stage IV, or recurrent. Participants in the safety run-in received open-label ruxolitinib and pemetrexed and cisplatin.
In the second part of the study, participants enrolled and randomized and received pemetrexed and cisplatin (open-label) and either ruxolitinib or placebo in a blinded manner. The dose of ruxolitinib administered was determined from the data produced in the safety run-in phase.
Treatment consisted of repeating 21-day cycles. Participants received infusions of pemetrexed and cisplatin on Day 1 of each cycle and ruxolitinib/placebo was self-administered during the entire cycle. Maintenance therapy with ruxolitinib or placebo in combination with pemetrexed, based on the original treatment assignment, was allowed for participants eligible for maintenance therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
An modified Glasgow Prognostic Score (mGPS) of 1 or 2 as defined below:
Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ruxolitinib · Drug: Pemetrexed · Drug: Cisplatin
Drug: Placebo · Drug: Pemetrexed · Drug: Cisplatin
5 mg tablets to be administered by mouth at dose selected from safety run-in phase (Ruxolitinib 15 mg twice daily (BID))
Also known as: Jakafi ®, Jakavi ®
5 mg matching placebo tablets to be administered by mouth
500 mg/m\^2 administered as an intravenous infusion over 10 minutes
Also known as: Alimta®
75 mg/m\^2 infused over 2 hours beginning 30 ± 5 minutes after the end of the pemetrexed infusion
Overall Survival (OS)
Overall survival is defined as the time from randomization to death due to any cause. Participants without death observed at the time of the analysis were censored at last date known to be alive. The median overall survival time was estimated using the Kaplan-Meier method. Overall survival was compared between treatment groups using log-rank test.
Time frame: Randomization until death due to any cause; up to 16 months or data cutoff 11FEB2016.
Progression-free Survival (PFS)
PFS is defined as the time from randomization until the earliest date of disease progression determined by investigator assessment of objective radiographic disease assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause if sooner. Progressive Disease (PD) is defined using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum Longest Diameter (LD) recorded since the treatment started or the appearance of one or more new lesions, unequivocal progression of non-target lesions or increase in disease burden for subjects with only nonmeasurable disease.
Time frame: Randomization to disease progression, or death due to any cause if sooner; up to 16 months or to the data cutoff 11FEB2016.
Objective Response Rate (ORR)
Objective response rate determined by radiographic disease assessments per RECIST (v1.1), by investigator assessment and was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) by Response Evaluation Criteria in Solid Tumours (RECIST) at any post baseline visit. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) for target lesions and assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI) : Complete Response (CR), Disappearance of all target and non-target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions with no worsening of non-target lesions and no new lesions; Overall Response (OR) = CR + PR.
Time frame: Baseline through end of study; up to 16 months or to the data cutoff 11FEB2016.
Duration of Response
For objective responders, the duration of response is defined as the difference of the end of response and the start of response. The start of a response was the first visit where the subject achieves PR or better based on RECIST v1.1 criteria. The end of response was the first visit after PD based on RECIST v1.1 criteria.
Time frame: From the start of response to the end of response; up to 16 months or to the data cutoff 11FEB2016.
Participants With Treatment-emergent Adverse Events (TEAEs)
A treatment-emergent AE was defined as an event occurring (or worsening of any pre-existing) after exposure to at least 1 dose of study drug. A treatment-related AE was defined as an event with a definite, probable, or possible causality to study medication. A serious AE is an event resulting in death, hospitalization, persistent or significant disability/incapacity, or is life threatening, a congenital anomaly/birth defect or requires medical or surgical intervention to prevent 1 of the outcomes above. The intensity of an AE was graded according to the National Cancer Institute common terminology criteria for adverse events (NCI-CTCAE) version 4.03: Grade 1 (Mild); Grade 2 (Moderate); Grade 3 (Severe); Grade 4 (life-threatening).
Time frame: Baseline through approximately 30 days post treatment discontinuation; up to 16 months or to the data cutoff 11FEB2016.
This study was conducted at 42 study centers (25 in the United States, 4 in Spain, 3 in France, 3 in Portugal, 2 in Denmark, 2 in Germany, 2 in Italy, 1 in the Netherlands).
| Milestone | Double-Blind Treatment: Ruxolitinib + Pemetrexed/Cisplatin | Double-Blind Treatment: Placebo Plus Pemetrexed/Cisplatin |
|---|---|---|
| Started | 39 | 37 |
| Completed | 14 | 11 |
| Not completed | 25 | 26 |
| Withdrew: Adverse event | 3 | 4 |
| Withdrew: Subject decision | 2 | 3 |
| Withdrew: Disease progression | 11 | 14 |
| Withdrew: Death | 5 | 1 |
| Withdrew: Noncompliance with study treatment | 1 | 1 |
| Withdrew: Study terminated by the sponsor | 1 | 0 |
| Withdrew: Physician decision | 0 | 2 |
| Withdrew: Multiple reasons for termination | 2 | 1 |
Overall survival is defined as the time from randomization to death due to any cause. Participants without death observed at the time of the analysis were censored at last date known to be alive. The median overall survival time was estimated using the Kaplan-Meier method. Overall survival was compared between treatment groups using log-rank test.
| months | Double-Blind Treatment: Ruxolitinib + Pemetrexed/Cisplatin | Double-Blind Treatment: Placebo Plus Pemetrexed/Cisplatin |
|---|---|---|
| Overall Survival (OS) | 7.5 (5.7 to NA) | 5.9 (4.0 to NA) |
PFS is defined as the time from randomization until the earliest date of disease progression determined by investigator assessment of objective radiographic disease assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause if sooner. Progressive Disease (PD) is defined using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum Longest Diameter (LD) recorded since the treatment started or the appearance of one or more new lesions, unequivocal progression of non-target lesions or increase in disease burden for subjects with only nonmeasurable disease.
| Months | Double-Blind Treatment: Ruxolitinib + Pemetrexed/Cisplatin | Double-Blind Treatment: Placebo Plus Pemetrexed/Cisplatin |
|---|---|---|
| Progression-free Survival (PFS) | NA (NA to NA) | NA (NA to NA) |
Objective response rate determined by radiographic disease assessments per RECIST (v1.1), by investigator assessment and was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) by Response Evaluation Criteria in Solid Tumours (RECIST) at any post baseline visit. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) for target lesions and assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI) : Complete Response (CR), Disappearance of all target and non-target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions with no worsening of non-target lesions and no new lesions; Overall Response (OR) = CR + PR.
| Participants | Double-Blind Treatment: Ruxolitinib + Pemetrexed/Cisplatin | Double-Blind Treatment: Placebo Plus Pemetrexed/Cisplatin |
|---|---|---|
| Overall Response | 12 | 13 |
| Complete Response | 0 | 0 |
| Partial Response | 12 | 13 |
| Stable Disease | 4 | 5 |
| Progressive Disease | 6 | 4 |
| Unable to Evaluate | 2 | 3 |
| Not Assessed | 15 | 12 |
For objective responders, the duration of response is defined as the difference of the end of response and the start of response. The start of a response was the first visit where the subject achieves PR or better based on RECIST v1.1 criteria. The end of response was the first visit after PD based on RECIST v1.1 criteria.
| weeks | Double-Blind Treatment: Ruxolitinib + Pemetrexed/Cisplatin | Double-Blind Treatment: Placebo Plus Pemetrexed/Cisplatin |
|---|---|---|
| Duration of Response | 20.14 (18.00 to 30.71) | 12.14 (6.00 to 24.00) |
A treatment-emergent AE was defined as an event occurring (or worsening of any pre-existing) after exposure to at least 1 dose of study drug. A treatment-related AE was defined as an event with a definite, probable, or possible causality to study medication. A serious AE is an event resulting in death, hospitalization, persistent or significant disability/incapacity, or is life threatening, a congenital anomaly/birth defect or requires medical or surgical intervention to prevent 1 of the outcomes above. The intensity of an AE was graded according to the National Cancer Institute common terminology criteria for adverse events (NCI-CTCAE) version 4.03: Grade 1 (Mild); Grade 2 (Moderate); Grade 3 (Severe); Grade 4 (life-threatening).
| Participants | Double-Blind Treatment: Ruxolitinib + Pemetrexed/Cisplatin | Double-Blind Treatment: Placebo Plus Pemetrexed/Cisplatin |
|---|---|---|
| Participants who had any TEAEs | 39 | 36 |
| Participants who had treatment-related TEAEs | 16 | 28 |
| Participants with any serious TEAE | 19 | 16 |
| Participants who had Grade 3 or higher TEAEs | 25 | 22 |
| Participants with a fatal TEAE | 4 | 4 |
| TEAEs related to reference therapy | 30 | 35 |
| Participants who were hospitalized due to TEAEs | 16 | 15 |
| Participants who discontinued drug due to TEAEs | 2 | 4 |
| Participants who interrupted drug due to TEAEs | 11 | 15 |
| Discontinued reference therapy due to TEAEs | 4 | 7 |
| Interrupted reference therapy due to TEAEs | 8 | 7 |
| Participants given concomitant meds due to TEAEs | 36 | 32 |
| Procedure/nondrug therapy due to TEAEs | 17 | 12 |
Collected over From the first dose of study medication through approximately 30 days post treatment discontinuation; up to 16 months or to the data cutoff 11FEB2016.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-Blind Treatment: Ruxolitinib + Pemetrexed/Cisplatin | — | 19/39 (48.7%) | 37/39 (94.9%) |
| Double-Blind Treatment: Placebo Plus Pemetrexed/Cisplatin | — | 16/37 (43.2%) | 36/37 (97.3%) |
| Event | Double-Blind Treatment: Ruxolitinib + Pemetrexed/Cisplatin | Double-Blind Treatment: Placebo Plus Pemetrexed/Cisplatin |
|---|---|---|
| PneumoniaInfections and infestations | 3/39 | 3/37 |
| AnemiaBlood and lymphatic system disorders | 3/39 | 1/37 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/39 | 2/37 |
| ConstipationGastrointestinal disorders | 0/39 | 2/37 |
| Atrial fibrillationCardiac disorders | 0/39 | 2/37 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/39 | 2/37 |
| General physical health deteriorationGeneral disorders | 0/39 | 2/37 |
| Pleuritic painRespiratory, thoracic and mediastinal disorders | 0/39 | 2/37 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/39 | 0/37 |
| VomitingGastrointestinal disorders | 2/39 | 0/37 |
| Event | Double-Blind Treatment: Ruxolitinib + Pemetrexed/Cisplatin | Double-Blind Treatment: Placebo Plus Pemetrexed/Cisplatin |
|---|---|---|
| NauseaGastrointestinal disorders | 20/39 | 32/37 |
| AnaemiaBlood and lymphatic system disorders | 15/39 | 12/37 |
| FatigueGeneral disorders | 13/39 | 14/37 |
| Decreased appetiteMetabolism and nutrition disorders | 5/39 | 14/37 |
| ConstipationGastrointestinal disorders | 13/39 | 13/37 |
| VomitingGastrointestinal disorders | 7/39 | 12/37 |
| AstheniaGeneral disorders | 7/39 | 12/37 |
| DiarrhoeaGastrointestinal disorders | 9/39 | 10/37 |
| StomatitisGastrointestinal disorders | 10/39 | 7/37 |
| CoughRespiratory, thoracic and mediastinal disorders | 6/39 | 9/37 |
The intent-to-treat (ITT) population consisted of participants that were randomized in the study.
| Age, Continuous(years) | Double-Blind Treatment: Ruxolitinib + Pemetrexed/Cisplatin | Double-Blind Treatment: Placebo Plus Pemetrexed/Cisplatin | Total |
|---|---|---|---|
| Mean | 61.6 ± 8.85 | 62.0 ± 8.55 | 61.8 ± 8.65 |
| Sex: Female, Male(Participants) | Double-Blind Treatment: Ruxolitinib + Pemetrexed/Cisplatin | Double-Blind Treatment: Placebo Plus Pemetrexed/Cisplatin | Total |
|---|---|---|---|
| Female | 15 | 14 | 29 |
| Male | 24 | 23 | 47 |
| Race (NIH/OMB)(Participants) | Double-Blind Treatment: Ruxolitinib + Pemetrexed/Cisplatin | Double-Blind Treatment: Placebo Plus Pemetrexed/Cisplatin | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 2 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 2 |
| White | 36 | 33 | 69 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 2 | 3 |
| Body Mass Index (BMI)(kg/m^2) | Double-Blind Treatment: Ruxolitinib + Pemetrexed/Cisplatin | Double-Blind Treatment: Placebo Plus Pemetrexed/Cisplatin | Total |
|---|---|---|---|
| Mean | 27.67 ± 6.402 | 27.65 ± 7.26 | 27.66 ± 6.787 |
Ran from Feb 2014 to primary completion in Feb 2016, 24 months.
Results were first posted in Jun 2017, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib
Carcinoma, Non-Small-Cell Lung →